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The transformation of a normal brain in epileptic (epileptogenesis) is associated
with extensive morpho-functional alterations, including cell death, axonal and dendritic
plasticity, neurogenesis, and others. Neurotrophic factors (NTFs) appear to be very
strongly implicated in these phenomena. In this review, we focus on the involvement of
fibroblast growth factor (FGF) family members. Available data demonstrate that the FGFs
are highly involved in the generation of the morpho-functional alterations in brain circuitries
associated with epileptogenesis. For example, data on FGF2, the most studied member,
suggest that it may be implicated both in seizure susceptibility and in seizure-induced
plasticity, exerting different, and apparently contrasting effects: favoring acute seizures
but reducing seizure-induced cell death. Even if many FGF members are still unexplored
and very limited information is available on the FGF receptors, a complex and fascinating
picture is emerging: multiple FGFs producing synergic or antagonistic effects one with
another (and/or with other NTFs) on biological parameters that, in turn, facilitate or oppose
transformation of the normal tissue in epileptic. In principle, identifying key elements
in these phenomena may lead to effective therapies, but reaching this goal will require
confronting a huge complexity. One first step could be to generate a “neurotrophicome”
listing the FGFs (and all other NTFs) that are active during epileptogenesis. This should
include identification of the extent to which each NTF is active (concentrations at the site
of action); how it is active (local representation of receptor subtypes); when in the natural
history of disease this occurs; how the NTF at hand will possibly interact with other NTFs.
This is extraordinarily challenging, but holds the promise of a better understanding of
epileptogenesis and, at large, of brain function.
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INTRODUCTION
Acquired epileptic syndromes are characterized by the sponta-
neous appearance of seizures in a previously healthy brain. Many
acquired epilepsies have an identifiable cause, such as a head
trauma, an episode of status epilepticus (SE), a stroke, or a brain
infection (Pitkänen and Sutula, 2002). It is thought that these
damaging insults set in motion a cascade of neurobiological alter-
ations that, in time, will lead to the occurrence of spontaneous
seizures and to the diagnosis of epilepsy. This phenomenon is
termed “epileptogenesis”.
Conventional “antiepileptic” agents exert only symptomatic
effects on seizures but do not interfere with epileptogenic pro-
cesses (Temkin, 2001). Moreover, a third of the people with
epilepsy do not get adequate seizure control with the current
medications (Schmidt and Sillanpää, 2012). Thus, there is an
urgent need formore effective (and better tolerated) treatments to
control drug-resistant seizures, as well as for innovative therapies
to prevent, stop or reverse the development of epilepsy in at-risk
individuals (Galanopoulou et al., 2012).
In principle, understanding the molecular mechanisms
underlying the neurobiological alterations occurring during
epileptogenesis and finding ways to manipulate them should
allow development of effective agents. Although the epileptogenic
process remains incompletely understood, recent molecular
studies began to elucidate the mechanisms that regulate some
components of the circuitry reorganizations (including cell death,
axonal and dendritic plasticity, neurogenesis and functional
alterations in ion channel and synaptic properties) that occur
during epileptogenesis and likely contribute to the development
of hyperexcitability and spontaneous seizures (Pitkänen and
Lukasiuk, 2011). Microarray-based gene expression studies
indicate that products of genes regulated during epileptogenesis
belong to a variety of functional classes, including signal
transduction, transcription regulation, neurogenesis and
immune response proteins (Pitkänen and Lukasiuk, 2009).
Which of these many molecular changes should be a target
for intervention? Neurotrophic factors (NTFs) appear to be very
strong candidates, because an extensive literature demonstrates
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their involvement in each of the above-mentioned cellular
alterations associated with epileptogenesis (Simonato et al., 2006;
Simonato and Zucchini, 2010): not only their trophic effects sug-
gest an involvement in cell death, neurogenesis and axonal sprout-
ing, but they also exert functional effects at the synaptic level, with
distinct modulatory actions at excitatory and inhibitory synapses
(Schinder and Poo, 2000). Furthermore, NTFs are greatly
involved in brain development, and epileptogenesis is thought
to recapitulate several aspects of developmental processes (Kim
et al., 2010; Simonato and Zucchini, 2010; Ueda et al., 2011).
Identification of the specific roles played by NTF families or
even single NTFs in the morpho-functional changes associated
with epileptogenesis is very difficult. It seems likely that multiple
NTFs are involved in the process at distinct phases and with
distinct roles (Simonato et al., 2006). Nonetheless, a few specific
molecules have gained particular interest and attention, like the
brain-derived neurotrophic factor (BDNF) and members of the
fibroblast growth factor (FGF) family, especially FGF2 (Simonato
et al., 2006). In fact, the combined supplementation of BDNF and
FGF2 in the epileptogenic area during the latency period between
an epileptogenic insult and the first spontaneous seizure has
been reported to produce a dramatic attenuation of the adaptive
morpho-functional changes occurring in the tissue (namely cell
loss, aberrant neurogenesis, sprouting of the mossy fibers—i.e.,
of hippocampal granule cell axons—and neuroinflammation),
ultimately leading to reduced frequency and severity of sponta-
neous seizures, i.e., a disease-modifying and maybe truly anti-
epileptogenic effect (Paradiso et al., 2009; Bovolenta et al., 2010;
Paradiso et al., 2011; Simonato et al., 2013).
These very promising results prompt further investigation of
the role played in epileptogenesis by neurotrophins like BDNF
and FGFs like FGF2. Here, we will focus on the involvement
of FGF family members in the morpho-functional alterations
associated with epilepsy. We will first summarize the biological
features of this class of NTF and then describe existing evidence
supporting their role in epileptic disorders and specifically in
epileptogenesis.
THE FGFs
The human FGFs contain 150–300 amino acids and have a
conserved core of 120 amino acids with 30–60% identity. The
family encompassed 18 members. FGF15 has not been identified
in humans and FGF19 has not been identified in mice and
rats, thus it has been hypothesized that they are the products
of orthologous genes. Four previously listed members, now
termed FGF homologous factors (FHF1-4), have been removed
from the original list of 23 (Goldfarb et al., 2007) because they
exert purely intracrine effects. FHF1, FHF2, FHF3 and FHF4,
which in the old nomenclature correspond respectively to FGF12,
FGF13, FGF11 and FGF14, are not secreted extracellularly and
act intracellularly in an FGF receptor-independent manner. They
interact with intracellular domains of voltage gated sodium
channels and with a neuronal mitogen-activated protein kinase
(MAPK) scaffold protein, islet-brain-2. FGF homologous factor
(FHFs) are thought to be mainly active in postnatal life, and their
only known role is in the regulation of excitability by association
with sodium channels (Itoh, 2010).
The currently classified 18 members of the mammalian FGF
family can be functionally sub-divided into canonical FGFs
and hormone-like FGFs (hFGFs) based on their paracrine or
endocrine actions (Itoh and Ornitz, 2011). Both sub-groups
mediate biological responses in an FGF receptor-dependent
manner, but hFGF can act over long distances like endocrine
hormones. Most FGFs are secreted proteins with cleavable
N-terminal secretion signal sequences. In this respect, FGF1 and
FGF2 are atypical, because they do not have these N-terminal
sequences, but they may nonetheless be released from damaged
cells or via exocytotic mechanism(s) independent from the
endoplasmic reticulum-Golgi pathway.
Almost all FGF effects are mediated by binding to cell surface
tyrosine kinase receptors (FGFRs). Heparin/heparan sulfate acts
as a cofactor for the binding of FGFs to FGFRs. FGF1, FGF2
and FGF3 can also directly translocate to the nucleus and act
in an intracrine manner (Itoh and Ornitz, 2011). Four genes,
FGFR1-FGFR4, have been identified in humans and mice that
encode for high-affinity FGFRs (FGFR1 through FGFR4). These
genes display substantial sequence homology and are similar in
their general structure: all are tyrosine kinase receptors with one
membrane-spanning domain and an extracellular ligand-binding
domain with three immunoglobulin-like motifs (Ig I, II and
III). The Ig-like domain III is an essential determinant of ligand
binding. FGFR1-FGFR3 encode two main versions of this domain
(termed IIIb and IIIc) generating, by alternative splicing, a total
of six FGFR proteins (FGFR 1b, 1c, 2b, 2c, 3b, 3c), whereas
FGFR4 generates a single protein (FGFR4). FGF binding to FGFRs
induces dimerization, receptor trans-phosphorylation and acti-
vation of four key downstream signaling pathways: RAS-RAF-
MAPK, PI3K-AKT, STAT and PLCγ (Beenken and Mohammadi,
2009; Turner and Grose, 2010).
Heparan sulfate interacts with heparan binding sites in
the FGFR Ig II domain and in the FGF molecule, favoring
protein-protein contacts at the dimer interface and thereby
sustaining dimerization. Dimerization enables tyrosine trans-
phosphorylation of the intracellular kinase domains and
generates docking sites for the recruitment and phosphorylation
of downstream signaling substrates, ultimately leading to
alterations in expression of specific genes and to the biological
effects. The acid box-containing linker between Ig domains I
and II may serve as auto-inhibitory control on heparan sulfate-
dependent receptor dimerization (Kalinina et al., 2012). The
endocrine hFGFs (FGF15/19, FGF21 and FGF23) bind to FGFRs
and heparin/heparan sulfate with very low affinity (Itoh, 2010).
FGF23 activates FGFR1c, which forms a complex with α-Klotho,
a single-pass transmembrane protein of 1,000 amino acids
with a short cytoplasmic domain predominantly expressed in
the kidney, parathyroid glands, and epithelial cells of choroid
plexuses in the brain. Similarly, FGF15/19 can bind to FGFR4
and β-Klotho, a protein structurally and functionally similar to
α-Klotho that is predominantly expressed in the liver, pancreas
and adipose tissue.
FGFs IN EPILEPSY
The production and release of many members of the FGF fam-
ily have been reported to be altered (increased in most cases)
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in epilepsy: these include FGF1, −2 and −5 (Gómez-Pinilla
et al., 1995; Riva et al., 1995; Cuevas and Giménez-Gallego,
1996; Simonato et al., 1998; Bregola et al., 2000), FGF7 and −22
(Terauchi et al., 2010; Lee et al., 2012) FGF8 and −17 (McCabe
et al., 2011; Zanni et al., 2011), as well as FHF4 (Hu et al., 2011)
and α-Klotho (Park et al., 2009). These observations prompted
investigations on possible functional roles played by the FGFs in
epileptic models and human syndromes. At present, data are still
rather fragmentary and incomplete. Figure 1 provides a schematic
representation of some of the best-characterized effects of FGFs
on the morpho-functional changes associated with epileptogene-
sis in the hippocampus. The member on which available informa-
tion is most robust and convincing is FGF2 (Zucchini et al., 2005,
2008), that will be therefore discussed separately and in greater
detail.
Research on FGFs involvement in epilepsy has been con-
ducted mainly in three types of models. First, acute seizure
models in which convulsions are produced in normal animals.
These include maximal electroshock (MES) and administration
of convulsant agents. Second, kindling: a model in which the
repeated administration to a discrete limbic brain area of an
initially subconvulsive electrical stimulation induces seizures that
progressively intensify in duration and severity, from focal to
secondarily generalized. Kindling can be evoked by stimulating
different areas, including the amygdala, hippocampus, piriform
cortex. Third, chemically (pilocarpine or kainate) or electrically
(self-sustained SE) evoked SE: these are models in which induc-
tion of an epileptogenic insult SE is followed by a latency period
during which the animals are apparently well and then by spon-
taneous recurrent seizures (SRSs), i.e., epilepsy. This situation
FIGURE 1 | Effects of FGFs on morpho-functional alterations associated
with epileptogenesis in the hippocampus. A schematic representation of
some of the best-characterized effects of FGFs on the morpho-functional
changes associated with epileptogenesis in the hippocampus: cell death,
astrocytosis, blood-brain barrier (BBB) damage, alterations in synaptogenesis
(density of excitatory or inhibitory terminals), axonal sprouting (like sprouting
of the mossy fibers), aberrant neurogenesis with newborn neurons in the
dentate gyrus hilus. Solid arrows indicate facilitation, dotted arrows inhibition
of a specific event. The name of the FGF members is framed in red to indicate
a putatively negative implication in epilepsy (favoring epileptogenesis), in
green to indicate a putatively positive implication (contrasting
epileptogenesis). Note that these are only tentative indications, because
evidence regarding the FGFs is often fragmentary and because the
patho-physiological consequences of each alteration are sometimes uncertain.
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most closely mimics the one occurring in humans with acquired
epilepsies.
FGF1
FGF1 (also known as acidic FGF, aFGF) has been reported to
be implicated in rodent models of epilepsy but, to date, it has
not been studied in the human disease (Naegele, 2009). MES in
rodents can produce epigenetic modifications of DNA leading to
increased neurogenesis. This phenomenon appears to be FGF1-
dependent and related to Gadd45b, a gene involved in DNA
repair and DNA 5-methylcytosine excision (Ma et al., 2009):
Gadd45b is responsible for demethylating regulatory promoter
regions in the genes encoding for FGF1 and BDNF. However,
the role in epilepsy of neurogenesis (and, based on these studies,
of FGF1) is still uncertain. Many consider it as a maladaptive
plastic change (Parent, 2007; Jung et al., 2009; Naegele, 2009;
Hattiangady and Shetty, 2010), implicating a pro-epileptic role
for FGF1. In contrast with this view, however, systemic admin-
istration of the recombinant human FGF1 has been reported to
exert anticonvulsant effects in kainate-induced convulsions and
mortality (Cuevas and Giménez-Gallego, 1996).
FGF5
Increased expression of FGF5 has been found shortly after acute
seizures, in association with an increased transcription of FGF2
and FGFR1 (Gómez-Pinilla et al., 1995). In contrast with FGF2,
whose constitutive expression is mainly in astrocytes (see below),
FGF5 is mostly found in neurons. Similar to FGF2 knock-out
mice, however, decreased expression levels of the intermediate
filament component glial fibrillary acidic protein (GFAP) has
been reported in FGF5 deficient mice, even if the density of
astrocytes remains unchanged (Reuss et al., 2003). FGF5 has
been hypothesized to favor astrocyte proliferation, based on the
observation that FGF5 and its high-affinity receptor FGFR1 IIIc
are overexpressed in astrocytic brain tumors (Allerstorfer et al.,
2008). Whether this effect also occurs in epileptogenesis and
favors epilepsy-associated astrocytosis is still unknown. Astrocy-
tosis contribute to induce many pathological events associated
with epileptogenesis, including increased inflammation and neu-
ronal hyperexcitability (Vezzani et al., 2011; Kim et al., 2012).
In functional contrast with these putative effects on
astrocytosis, FGF5 may contribute to the stabilization of the
blood—brain barrier (BBB). A reduction of GFAP protein
levels has been observed in the perivascular astroglial endfeet
of FGF5 (and FGF2) deficient mice (Reuss et al., 2003),
resulting in increased BBB permeability, an event associated with
epileptogenesis. Therefore, FGF5 appears to exert contrasting
effects in epilepsy development: on one hand, it may protect the
BBB; on the other hand, it may favor reactive astrocytosis.
FGF7 AND FGF22
FGF22 and FGF7 have been reported to promote the organization
of excitatory and inhibitory presynaptic terminals, respectively,
as target-derived presynaptic organizers. These factors are target-
derived molecules that promote differentiation of neuritic seg-
ments into presynaptic nerve terminals. FGF22 and FGF7 are
expressed in the CA3 pyramidal neurons of the rodent and human
(at least FGF22) hippocampus (Umemori et al., 2004; Katoh and
Katoh, 2005; Terauchi et al., 2010; Lee et al., 2012). The formation
of excitatory or inhibitory synaptic contacts on dendrites of hip-
pocampal CA3 pyramidal neurons is specifically impaired in mice
lacking FGF22 or FGF7, respectively. Specifically, the clustering
of vesicles containing the excitatory neurotransmitter glutamate
is impaired in FGF22 deficient mice, whereas the clustering of
inhibitory, GABA-containing vesicles is reduced in FGF7 deficient
mice (Jones and Basson, 2010). These presynaptic defects are res-
cued by postsynaptic expression of the appropriate FGF, demon-
strating that there is an absolute requirement of FGF7 during the
formation of inhibitory GABAergic synapses and of FGF22 during
excitatory glutamatergic synaptogenesis. The differential effects of
FGF22 and FGF7 are likely due to distinct synaptic localizations
and employment of different signaling pathways.
The implications for epilepsy are of course opposite. FGF22
knock-out mice (with reduced excitatory synapses) are resistant
to epileptic seizures, whereas FGF7 knock-outmice (with reduced
inhibitory synapses) are prone to seizures (Terauchi et al., 2010;
Lee et al., 2012). In addition, increased neurogenesis and mossy
fiber sprouting have been reported in FGF7 knock-out mice
during post-SE epileptogenesis, both events that may also favor
susceptibility to epilepsy development in these mice (Lee et al.,
2012). Therefore, FGF7 activation may be capable of decreasing
vulnerability to epilepsy by multiple mechanisms. In contrast,
epileptogenesis-associated aberrant neurogenesis and cell death
in the hippocampal dentate gyrus hilus are suppressed in FGF22
knock-out mice (Lee and Umemori, 2013), suggesting that inhi-
bition of FGF22 may alleviate epileptogenesis.
FGF8 AND FGF17
FGF8 and FGF17 are implicated in two epileptogenic human
neurological disorders. Recently, FGF8 gene mutations have been
identified in recessive holoprosencephaly and in septo-optic dys-
plasia (Moebius syndrome), and FGF17 gene chromosomic dele-
tion in Dandy–Walker malformation (McCabe et al., 2011; Zanni
et al., 2011). In all these diseases, patients can experience sponta-
neous seizures.
FHF4
The intracrine FHF4 (FGF14 according to the old nomenclature)
also seems to be involved in the morpho-functional alterations
associated with epilepsy. De-repression of FGF14 gene expres-
sion is obtained in conditional neuron-restrictive silencer factor
(NRSF) knock-out mice (Hu et al., 2011). In fact, the degree of
up-regulation of FHF4 following kainate-induced SE is signifi-
cantly increased in the cortex of NRSF knock-out mice compared
with controls. In the kindling model, these mice exhibit dramat-
ically accelerated seizure progression, prolonged after-discharge
duration and increased mossy fiber sprouting compared with
controls. Thus, FHF4 appears to favor epileptogenesis. The mech-
anism of this effect remains unknown, but it can be hypothesized
that it depends on increased neurogenesis and/or synaptogenesis
(Wang et al., 2002; Hu et al., 2011).
α-KLOTHO
Pathological activation of α-Klotho may be implicated in
phenylketonuria (PKU), an autosomal recessive disorder caused
by a deficiency of phenylalanine hydroxylase, an enzyme that
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catalyzes the conversion of phenylalanine to tyrosine. The
resultant hyper-phenylalaninemia causes mental retardation,
seizures, and abnormalities in behavior and movement. The
mechanism of this disease remains incompletely understood,
but an implication of the FGF family has been proposed based
on the observation of an α-Klotho-dependent increase in
Na+/K+-ATPase activity (Park et al., 2009; Itoh, 2010).
FGF2 AND EPILEPSY
EXPRESSION IN THE BRAIN
FGF2 (basic FGF, bFGF) expression is developmentally regulated.
It is highly expressed in neurons in the fetal brain and, later in
development, in glia cells (Caday et al., 1990; Torelli et al., 1990);
its levels increase progressively in early postnatal life, and then
remain high in the adult and aged rat brain (Riva and Mocchetti,
1991).
BIOLOGICAL ACTIVITIES
FGF2 is thought to play a critical role in cell-cell signaling
between neurons, astrocytes and microglia during development
(Gremo and Presta, 2000). In adults, FGF2 can regulate
proliferation of neural stem cells and neuronal survival (Bikfalvi
et al., 1997; Hefti, 1997). Furthermore, it enhances axonal
branching (Waliche, 1988; Aoyagi et al., 1994; Abe et al., 2001;
Szebenyi et al., 2001) and synaptogenesis (Li et al., 2002) in
neurons.
FGF2 exerts neuroprotective effects against a wide variety of
insults, reducing brain cellular damage and improving functional
recovery in experimental models of stroke, epilepsy, traumatic
brain and spinal cord injury (Liu and Holmes, 1997a; Teng
et al., 1999; Li and Stephenson, 2002; Zucchini et al., 2008). This
neuroprotective effect seems to depend on interference with a
number of signaling pathways, including expression and gating of
N-methyl-D-aspartate (NMDA) receptors, maintenance of Ca2+
homeostasis, regulation of reactive oxygen species (ROS) detox-
ifying enzymes and strengthening of anti-apoptotic pathways
(Acharya et al., 2008).
In vitro, FGF2 increases survival, proliferation and differen-
tiation of hippocampal neurons (Vicario-Abejon et al., 1995;
Lowenstein and Arsenault, 1996). Interestingly, low FGF2 levels
predominantly lead to the generation of neurons, whereas high
levels generate glia and neurons (Vescovi et al., 1993; Qian et al.,
1997). Similar effects are also observed in vivo. Neurogenesis is
inhibited by injection of an anti-FGF2 antibody and increased by
FGF2 injection in P1 rats (Tao et al., 1997; Cheng et al., 2002).
The effects of exogenous FGF2 is also observed in the adult brain,
in areas of constitutive neurogenesis, i.e., subgranular zone of the
dentate gyrus and subventricolar zone (Wagner et al., 1999). FGF2
is the most potent known mitotic agent for adult neural stem
and progenitor cells. Moreover, it regulates astroglial cell differ-
entiation, functions, and transition to the “reactive” phenotype
observed after lesions (Reuss et al., 2003). As in FGF5 deficient
mice, a reduction of GFAP protein levels has been observed in
the perivascular astroglial endfeet of FGF2 knock-outmice (Reuss
et al., 2003), which results in increased BBB permeability.
FGF2 accelerates bifurcation and growth of axonal branches in
cultured rat hippocampal neurons (Aoyagi et al., 1994). A greater
number of axon branches is expected to produce a greater number
of synaptic contacts and, indeed, local application of FGF2 has
been found to increase the number of morphologically mature
and functionally active excitatory synapses between hippocampal
neurons (Li et al., 2002).
FGF2 AND EPILEPSY
Based on its biological properties, FGF2 seems particularly likely
to be involved in epileptogenesis. Indeed, (1) seizures increase
FGF2 mRNA and protein levels in specific brain areas and up-
regulate the expression of FGFR1 receptors; (2) acute intra-
hippocampal injection of FGF2 causes seizures, while chronic
i.c.v. infusion of low dose FGF2 does not affect kainate seizures
but promotes behavioral recovery and reduces hippocampal dam-
age; (3) kainate seizure severity is not altered in FGF2 knock-out
mice, but is increased in FGF2 over-expressing mice.
FGF2 gene expression is induced with similar patterns in
different acute seizure models (Riva et al., 1992; Bugra et al., 1994;
Follesa et al., 1994; Gall et al., 1994; Riva et al., 1994; Gómez-
Pinilla et al., 1995; Kondratyev et al., 2002). This phenomenon
is fast, marked and transient, peaking at 6–24 h in different
hippocampal subfields and in the cortex. In the hippocampus
of naive rats, FGF2 is expressed diffusely in astrocytes and in
CA2 pyramidal neurons (Ernfors et al., 1990; Gomez-Pinilla
et al., 1992; Woodward et al., 1992). Following acute seizures,
increased FGF2 mRNA levels in these cell populations, as well
as new expression in CA1 pyramidal neurons and in dentate
gyrus granule cells have been observed (Gall et al., 1994; Riva
et al., 1994). In the kindling model, induction of FGF2 mRNA
expression is observed in a more pronounced manner after a
single after-discharge, not accompanied by behavioral seizures,
than after a fully kindled, generalized tonic-clonic seizure lasting
more than a minute (Simonato et al., 1998; Bregola et al., 2000).
In addition, FGF2 expression in limbic regions has been reported
to be more pronounced after partial than after generalized elec-
troshock seizures (Follesa et al., 1994). These observations suggest
that the duration and intensity of seizures within a specific area
does not necessarily correlate with the magnitude of FGF2mRNA
level increase, and that FGF2 may be more directly implicated
with epileptogenesis than with generalized seizure expression.
Induction of mRNA for FGF2 is typically followed by an increase
in FGF2 protein: FGF2-like immunoreactivity is detectable 6
h following seizures, peaks after about 24 h and may remain
elevated up to 30 days, being mainly localized in the nuclei
of astrocytes (Humpel et al., 1993; Gómez-Pinilla et al., 1995;
Ballabriga et al., 1997; Gwinn et al., 2002). Increased levels are
mainly observed for the high molecular weight isoforms of FGF2,
which contain nuclear targeting sequences, and therefore may
enter the nucleus and influence gene regulation, activating pro-
grams for cellular plasticity or proliferation (Gwinn et al., 2002).
Therefore, the transient pattern of FGF2 mRNA elevation may
have prolonged translational effect influencing long-term plas-
ticity changes. Finally, seizure-induced increases in the neuronal
and astrocytic expression of a high-affinity FGF receptor (FGFR1)
have been found in an epilepsy model (Bugra et al., 1994; Van
Der Wal et al., 1994; Gómez-Pinilla et al., 1995). A strong FGFR3
staining has also been found in reactive microglia in several brain
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areas, including the hippocampus, 30 days after kainate injection
(Ballabriga et al., 1997). These observations lead to the notion
that epileptogenic seizures co-ordinately increase the expression
of FGF2 and of its receptor(s). The hypothesis that these events
may take part in the plastic changes associated with epilepsy has
been pharmacologically and genetically investigated.
Injection of FGF2 into the dentate region of the ventral hip-
pocampus causes an immediate excitatory effect culminating
in EEG and behavioral seizures (Liu and Holmes, 1997b). In
contrast, the chronic infusion of low FGF2 doses into the cere-
bral ventricles does not modify latency and duration of kainate
seizures, but prevents seizure-induced hippocampal cell loss and
improves long-term behavioral recovery (Liu et al., 1993; Liu
and Holmes, 1997a). This neuroprotective action may depend on
the induction of activin A (ActA), a cytokine belonging to the
transforming growth factor-beta superfamily. When co-injected
with kainate in the hippocampus, FGF2 prevents the loss of CA3
neurons in mice. In mice treated with kainate and FGF2, but
not in those treated with kainate alone, ActA-immunoreactivity
is high in pyramidal neurons (Tretter et al., 2000) and FGF2
fails to protect CA3 neurons against kainate-induced death in the
presence of the ActA-neutralizing protein follistatin (Tretter et al.,
2000).
Studies in FGF2 knock-out and transgenic mice have extended
these pharmacological findings. The FGF2 knock-out mice
(Ortega et al., 1998) are viable, fertile and without any obvi-
ous phenotypical difference from their wild-type littermates, but
exhibit a significant reduction in the number of neurons in the
neocortex and a delayed would healing. The susceptibility to
seizures of FGF2 knock-out mice has been studied in the kainate
model (Yoshimura et al., 2001). The severity of kainate seizures
did not differ between knock-out and wild-type mice. However,
while an increase in FGF2 protein levels and neuroproliferation
was observed in the hippocampus of wild-type mice, very low lev-
els of neurogenesis were observed in the knock-outs (Yoshimura
et al., 2001). High FGF2 levels were restored in the mutant mice
using a viral gene delivery system, leading to levels of neurogenesis
comparable to those of wild-type littermates. These data suggest
that seizure-induced FGF2 overexpression is necessary and suffi-
cient to prime proliferation of neural progenitor cells in the adult
hippocampus (Yoshimura et al., 2001).
In an attempt to further elucidate the effect of FGF2 in
epilepsy, we studied transgenic mice (TgFGF2) expressing the
human FGF2 (Coffin et al., 1995; Fulgham et al., 1999). By gross
examination, these mice are affected by skeletal malformations,
such as shortening and flattening of long bones and moderate
macrocephaly (Coffin et al., 1995). In addition, without having
any spontaneous vascular defect, they exhibit a predisposition
to angiogenic reactions with subsequent amplified angiogenesis
(Fulgham et al., 1999). TgFGF2 mice display increased FGF2
expression in hippocampal pyramidal neurons and dentate
granule cells. Increased density of glutamatergic synaptic vesicles
is observed in the hippocampus, and electrophysiological data
confirm an increase in excitatory inputs to CA1, suggesting the
presence of a latent hyperexcitability (Zucchini et al., 2008).
Indeed, TgFGF2 mice display increased susceptibility to kainate-
induced seizures compared with wild-type littermates, in that
latency to generalized seizure onset is reduced, while behavioral
seizure scores and lethality are increased. Wild-type and TgFGF2
mice with similar seizure scores were employed for examining
seizure-induced cellular consequences. Neurogenesis and mossy
fiber sprouting are not significantly different between the two
groups. By contrast, cell damage is significantly lower in TgFGF2
mice, especially in the areas of FGF2 overexpression (CA1 and
CA3), indicating reduction of seizure-induced necrosis and apop-
tosis. These data are in good agreement with the neuroprotective
action of FGF2 in injury models, and it can be hypothesized
(as above) that seizures prompt the over-production of FGF2
in astrocytes and neurons and, in turn, this newly produced
FGF2 enhances the production of ActA in selected neurons.
In the hippocampus, ActA may reach high levels in CA1 and
CA3 neurons, protecting these cell types from injury (Mattson,
2000). Accordingly, in FGF2 transgenic mice we observed the
preservation from degeneration of CA1 and CA3 neurons, but
not of those in the hilus of the dentate gyrus. Finally, we explored
possible long-term synaptic rearrangements, like the sprouting
of mossy fibers. Under control condition, neither wild-type of
TgFGF2 mice display sprouting of the mossy fibers. Thirty days
after kainate treatment, sprouting is observed in similar grade
both in transgenic and in control mice (Zucchini et al., 2008).
Altogether, these data suggest that FGF2 may be implicated
in seizure susceptibility and in seizure-induced plasticity, exert-
ing different, and apparently contrasting effects: favoring acute
seizures but reducing seizure-induced cell death. Coherent with
this idea, FGF2 has been suggested to be implicated in the precon-
ditioning effect of brief, non-injurious seizures that can protect
against cell death induced by otherwise harmful insults, like
adrenalectomy or kainate-induced SE (Kelly and McIntyre, 1994;
Masco et al., 1999; Kondratyev et al., 2001). These apparently con-
trasting effects could depend on activation of different receptor
subtypes (Simonato et al., 2006), a hypothesis not yet explored.
In addition to rodent studies, the implication of FGF2 has
been investigated in human epilepsy-associated malformations
of cortical development by autoptic analysis and corticectomy
specimens. The data support the notion that FGF2 favors epilepsy
development by altering gliogenesis and maturation of cortical
neurons from migrating neuroblasts (Ueda et al., 2011).
CONCLUSIONS
The data described in this review clearly demonstrate that the
FGFs are highly involved in the generation of the morpho-
functional alterations in brain circuitries associated with
epileptogenesis, that will eventually lead to unbalanced control
of excitability and spontaneous seizures, i.e., epilepsy. As noted,
information is still very incomplete, with many FGF members
still unexplored and with very limited information on the FGF
receptors. Moreover, these findings should be integrated with
others on the involvement of other NTF families (Simonato et al.,
2006).
Altogether, it seems likely that the morphology and function
of adult brain circuits is regulated in a highly redundant manner.
With reference to epilepsy, the emerging picture is impressively
complex: multiple NTFs implicated at different levels and in
different areas, producing synergic or antagonistic effects on
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biological parameters that, in turn, may facilitate or oppose the
transformation of a normal tissue in epileptic. Therefore, even
if, in principle, identifying key elements in these phenomena
may lead to effective therapies, reaching this goal will require
confronting this huge complexity.
Dissecting out this situation is not trivial at all. One first
step could be to generate a sort of “neurotrophicome” listing
all NTFs (and NTF receptors) that are active during epileptoge-
nesis. This would require identification of the extent to which
each NTF is active (concentrations at the site of action); how
it is active (local representation of receptor subtypes, including
low-affinity receptors); when in the natural history of disease
this occurs; how the NTF at hand will possibly interact with
other NTFs. Once a sufficiently realistic picture of this “neu-
rotrophicome” will become available, it will still be needed to
determine a strategy for intervention and to develop appropri-
ate tools to manipulate (and possibly correct) the pathological
situation.
All this is extraordinarily challenging but, at the same time,
is extremely fascinating and holds the promise of outstanding
rewards: a better understanding of the brain function, and maybe
a cure for epilepsy and other neurological diseases.
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